Palvella Reports Positive Phase 3 Data, Expands Pipeline Post-Merger

TL;DR

**PVLA's positive Phase 3 data for QTORIN rapamycin is a game-changer for rare disease patients and a strong buy signal for investors, despite ongoing losses.**

AI Summary

Palvella Therapeutics, Inc. (PVLA) completed a merger on December 13, 2024, with Legacy Palvella, shifting its focus to developing novel therapies for rare skin diseases and vascular malformations. The company reported positive topline results in February 2026 from its Phase 3 SELVA study for QTORIN rapamycin in microcystic lymphatic malformations (mLM), meeting the primary endpoint with a +2.13 (p<0.001) improvement in mLM-IGA. Additionally, positive topline efficacy results were announced in December 2025 from the Phase 2 TOIVA study for QTORIN rapamycin in cutaneous venous malformations (VMs), achieving nominal statistical significance (p<0.001) on multiple endpoints. PVLA expanded its QTORIN rapamycin program into angiokeratomas in September 2025 and introduced a new product candidate, QTORIN pitavastatin, for disseminated superficial actinic porokeratosis in November 2025. The company has historically incurred significant operating losses and anticipates continued losses for several years, having never generated revenue from product sales.

Why It Matters

Palvella's positive Phase 3 results for QTORIN rapamycin in microcystic LMs and Phase 2 results in cutaneous VMs are critical for investors, signaling potential market entry into areas with no FDA-approved therapies. This progress could offer significant relief to patients suffering from these debilitating rare diseases, improving their quality of life. For employees, these clinical successes validate their work and secure future development. In a competitive landscape, successful clinical trials and potential market exclusivity from Orphan Drug and Breakthrough Therapy designations could position Palvella as a leader in rare dermatological and vascular conditions, attracting further investment and partnerships.

Risk Assessment

Risk Level: high — Palvella Therapeutics faces a high risk level due to its history of significant operating losses and zero revenue from product sales, indicating a reliance on future financing. The company's success is heavily dependent on the successful clinical development and regulatory approval of QTORIN rapamycin and other product candidates, which are based on a novel and unproven QTORIN platform, as stated in the 'Summary of Principal Risk Factors'. Failure to obtain additional funding or regulatory approvals would materially and adversely affect its business.

Analyst Insight

Investors should closely monitor Palvella's progress towards regulatory submissions and commercialization plans for QTORIN rapamycin, given the positive Phase 3 results. While the clinical data is promising, the company's lack of revenue and need for additional funding warrant caution; consider this a speculative investment with high growth potential if approvals are secured.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $196.7 million — Aggregate market value of common equity held by non-affiliates (As of June 30, 2025, indicating company size)
• 14,313,659 — Shares of Common Stock outstanding (As of March 25, 2026, indicating current share count)
• +2.13 — mLM Investigator Global Assessment (mLM-IGA) improvement (Primary endpoint achievement in Phase 3 SELVA study for QTORIN rapamycin (p<0.001))
• 30,000+ — Estimated diagnosed patients in the U.S. with microcystic LMs (Represents the potential market size for QTORIN rapamycin)
• 51 — Participants enrolled in SELVA Phase 3 trial (Exceeded target enrollment for the microcystic LM study)
• 3 years — Minimum age for QTORIN rapamycin treatment in SELVA study (Indicates the broad patient population targeted)

Key Players & Entities

• Palvella Therapeutics, Inc. (company) — Registrant and clinical-stage biopharmaceutical company
• Pieris Pharmaceuticals, Inc. (company) — Predecessor company to Palvella Therapeutics, Inc. before the Merger
• Legacy Palvella (company) — Acquired company in the Merger, now a wholly owned subsidiary
• QTORIN rapamycin (company) — Lead product candidate in clinical development
• QTORIN pitavastatin (company) — New QTORIN product candidate announced in November 2025
• FDA (regulator) — U.S. Food and Drug Administration
• Nasdaq Capital Market (company) — Exchange where PVLA Common Stock is registered
• SEC (regulator) — U.S. Securities and Exchange Commission
• Polo Merger Sub, Inc. (company) — Wholly owned subsidiary of Pieris involved in the Merger

FAQ

Risk Factors

• History of Operating Losses and Anticipated Future Losses [high — financial]: The company has historically incurred significant operating losses and anticipates continued losses for several years. It has never generated revenue from product sales, indicating a substantial reliance on external funding to sustain operations and development efforts.
• Dependence on Regulatory Approval for Product Commercialization [high — regulatory]: Palvella's success is contingent upon obtaining regulatory approval for its product candidates, such as QTORIN rapamycin for microcystic lymphatic malformations and cutaneous venous malformations. Delays or failures in the regulatory process could significantly impact the company's ability to generate revenue.
• Competition in Rare Disease and Vascular Malformation Markets [medium — market]: The markets for rare skin diseases and vascular malformations may attract competition from other biotechnology and pharmaceutical companies. Palvella's ability to compete will depend on the efficacy, safety, and pricing of its therapies compared to existing or emerging treatments.
• Reliance on Key Personnel and Third-Party Manufacturers [medium — operational]: The company's operations, including research and development and manufacturing, may rely on a small number of key personnel and third-party manufacturers. Any disruption in these areas could adversely affect product development and supply.

Industry Context

Palvella Therapeutics operates in the specialized biotechnology sector focused on rare diseases and vascular malformations. This niche market often presents opportunities for targeted therapies due to unmet medical needs, but also requires significant investment in clinical development and regulatory pathways. The competitive landscape includes other biopharmaceutical companies developing novel treatments for similar conditions.

Regulatory Implications

The company's future hinges on successful navigation of the FDA and other regulatory bodies for its drug candidates, particularly QTORIN rapamycin. Positive Phase 3 results for mLM are a significant step, but further regulatory review and potential approval are critical. Any delays or setbacks in the approval process pose a substantial risk.

What Investors Should Do

1. Monitor upcoming regulatory filings and decisions for QTORIN rapamycin.
2. Evaluate the long-term financial strategy for funding continued development and potential commercialization.
3. Assess the competitive landscape and market penetration potential for QTORIN rapamycin and QTORIN pitavastatin.

Key Dates

• 2024-12-13: Merger Completion — Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) completed its merger with Legacy Palvella, shifting the company's focus to rare skin diseases and vascular malformations.
• 2025-09-01: QTORIN Rapamycin Program Expansion — The company expanded its QTORIN rapamycin program to include angiokeratomas, indicating pipeline diversification.
• 2025-11-01: Introduction of QTORIN Pitavastatin — A new product candidate, QTORIN pitavastatin, was introduced for disseminated superficial actinic porokeratosis, further broadening the development pipeline.
• 2025-12-01: Phase 2 TOIVA Study Topline Results — Positive topline efficacy results were announced for QTORIN rapamycin in cutaneous venous malformations, achieving nominal statistical significance (p<0.001) on multiple endpoints.
• 2026-02-01: Phase 3 SELVA Study Topline Results — Positive topline results were reported for QTORIN rapamycin in microcystic lymphatic malformations, meeting the primary endpoint with a +2.13 (p<0.001) improvement in mLM-IGA.

Glossary

Merger

The combination of two companies, in this case, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) and Legacy Palvella. (This event marks the strategic shift and rebranding of the company, defining its current operational focus.)

QTORIN rapamycin

A drug candidate developed by Palvella Therapeutics, Inc. for the treatment of rare skin diseases and vascular malformations. (This is the company's lead therapeutic agent, with positive Phase 2 and Phase 3 results reported for different indications.)

Microcystic lymphatic malformations (mLM)

A type of vascular malformation characterized by small, fluid-filled cysts within the lymphatic system. (This is a key indication for QTORIN rapamycin, with the Phase 3 SELVA study meeting its primary endpoint for this condition.)

Investigator Global Assessment (IGA)

A clinical trial endpoint used to measure the overall severity of a disease as judged by the investigator. (The primary endpoint of the SELVA Phase 3 study was an improvement in mLM-IGA, demonstrating the drug's efficacy.)

Cutaneous venous malformations (VMs)

Abnormalities of blood vessels in the skin that can cause cosmetic and functional issues. (This is another indication for QTORIN rapamycin, for which positive Phase 2 results have been announced.)

Disseminated superficial actinic porokeratosis

A rare skin disorder characterized by multiple, small, scaly patches on sun-exposed skin. (This is an indication for the company's new product candidate, QTORIN pitavastatin.)

Year-Over-Year Comparison

As this is the first 10-K filing post-merger and with a new strategic focus, direct year-over-year comparisons of key financial metrics like revenue, net income, and margins are not applicable. The filing reflects a transition from a predecessor company to Palvella Therapeutics, Inc., with a new pipeline and development strategy centered on rare skin diseases and vascular malformations. New risks related to clinical trial success, regulatory approval, and commercialization of these specific therapies are now paramount.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PVLA The Nasdaq Capital M
• $2.6 million — roducts Clinical Trials Grant for up to $2.6 million supporting the SELVA Phase 3 study and
• $1.1 million — e SELVA Phase 3 study and have received $1.1 million of proceeds to date. 4 QTORIN Rapam

Filing Documents

• pvla-20251231.htm (10-K) — 3683KB
• pvla-ex4_1.htm (EX-4.1) — 37KB
• pvla-ex10_30.htm (EX-10.30) — 161KB
• pvla-ex19_1.htm (EX-19.1) — 130KB
• pvla-ex21_1.htm (EX-21.1) — 5KB
• pvla-ex23_1.htm (EX-23.1) — 5KB
• pvla-ex31_1.htm (EX-31.1) — 17KB
• pvla-ex31_2.htm (EX-31.2) — 17KB
• pvla-ex32_1.htm (EX-32.1) — 11KB
• pvla-ex32_2.htm (EX-32.2) — 11KB
• pvla-ex97_1.htm (EX-97.1) — 58KB
• img52950341_0.jpg (GRAPHIC) — 64KB
• img52950341_1.jpg (GRAPHIC) — 186KB
• img52950341_2.jpg (GRAPHIC) — 130KB
• img52950341_3.jpg (GRAPHIC) — 78KB
• img52950341_4.jpg (GRAPHIC) — 207KB
• img52950341_5.jpg (GRAPHIC) — 400KB
• img52950341_6.jpg (GRAPHIC) — 201KB
• img52950341_7.jpg (GRAPHIC) — 113KB
• img52950341_8.jpg (GRAPHIC) — 210KB
• img52950341_9.jpg (GRAPHIC) — 141KB
• img52950341_10.jpg (GRAPHIC) — 243KB
• img52950341_11.jpg (GRAPHIC) — 174KB
• img52950341_12.jpg (GRAPHIC) — 169KB
• 0001193125-26-133372.txt (&nbsp;) — 18066KB
• pvla-20251231.xsd (EX-101.SCH) — 1430KB
• pvla-20251231_htm.xml (XML) — 1784KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 49 Item 1B. Unresolved Staff Comments 104 Item 1C. Cybersecurity 104 Item 2.

Properties

Properties 104 Item 3.

Legal Proceedings

Legal Proceedings 105 Item 4. Mine Safety Disclosures 105 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 106 Item 6. [Reserved] 106 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 107 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 122 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 122 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 122 Item 9A.

Controls and Procedures

Controls and Procedures 122 Item 9B. Other Information 123 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 123 PART III Item 10. Directors, Executive Officers and Corporate Governance 124 Item 11.

Executive Compensation

Executive Compensation 124 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 124 Item 13. Certain Relationships and Related Transactions, and Director Independence 124 Item 14. Principal Accounting Fees and Services 124 PART IV Item 15. Exhibits, Financial Statement Schedules 125 Item 16. Form 10-K Summary 126 GENERAL INFORMATION Unless otherwise stated or the context requires otherwise, references in this Annual Report on Form 10-K to "Palvella," the "company," the "Company," "we," "us," "our" or similar designations refer to Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) and its subsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, trade names or registered marks of their respective owners. References to "Pieris" refer to Pieris Pharmaceuticals, Inc., our predecessor company prior to the Merger (as defined below) and references to "Legacy Palvella" or "Palvella" refer to Palvella Therapeutics, Inc. prior to the Merger and our wholly owned subsidiary upon the consummation of the Merger (as defined below). On December 13, 2024 (the "Closing Date"), Palvella Therapeutics, Inc., a Nevada corporation (the "Company" or "Palvella") (previously named Pieris Pharmaceuticals, Inc. and our predecessor company ("Pieris")), consummated the previously announced merger pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 23, 2024 (the "Merger Agreement"), by and among the Company, Polo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Pieris (the "Merger Sub"), and Palvella Therapeutics, Inc., a Delaware corporation ("Legacy Palvella"). Pursuant to the Merger Agreement, on the Closing Date, (i) Merger Sub merged with and into Legacy Palvella, with Legacy Palvella as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly owned subsi

Forward-looking statements contained in this Form 10-K include, but are not limited to, statements about

Forward-looking statements contained in this Form 10-K include, but are not limited to, statements about: the strategies, prospects, plans, expectations and objectives of management of our future operations; the potential of, and expectations regarding our programs, including QTORIN rapamycin, QTORIN pitavastatin, and research-stage opportunities, including their expected therapeutic potential and market opportunity; the need to hire additional personnel and our ability to attract and retain such personnel; the ability to protect and enhance our products, proprietary technologies and intellectual property, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; developments and projections relating to our competitors or industry; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our financial performance; expectations concerning our relationships and actions with third parties, including any licenses and collaborations with such third parties; future regulatory, judicial and legislative changes or uncertainties in our industry in the United States, Europe, and other jurisdictions, including due to uncertainty resulting from the recent change in U.S. administration and shift in government policy and evolving regulatory environment; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates; our ability to utilize our proprietary drug development platform to develop a pipeline of product candidates to address unmet needs in rare skin disease and vascular malformation indications; the outcome of clinical trials of our product candidates, including the ability of those trials to satisfy relevant governmental and regulatory requirements; the timing of availabilit

View Full Filing

View this 10-K filing on SEC EDGAR